Bio-TechneMIL:1TECH -0.70%61 Days Payable is 21.87 as of Mar. 2026, which is 28% below its 10-year median of 30.20. GuruFocus rates MIL:1TECH with a GF Score™ of 61/100 and a GF Value™ of €63.40 (Fairly Valued). The stock has 8 warning signs investors should review. Among 703 Biotechnology companies, Bio-Techne ranks worse than 86.34% on this metric.
Bio-Techne's average Accounts Payable for the
three
months ended in Mar. 2026 was €21 Mil. Bio-Techne's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €89 Mil.
Hence, Bio-Techne's Days Payable for the
three
months ended in Mar. 2026 was 21.87.
The historical rank and industry rank for Bio-Techne's Days Payable or its related term are showing as below:
MIL:1TECH'
s Days Payable Range Over the Past 10 Years
Min: 23.55 Med: 30.2 Max: 38.32
Current: 23.55
During the past 13 years, Bio-Techne's highest Days Payable was 38.32. The lowest was 23.55. And the median was 30.20.
MIL:1TECH's Days Payable is ranked worse than 86.34% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs MIL:1TECH: 23.55
Bio-Techne's Days Payable
declined
from Mar. 2025 (29.56) to Mar. 2026 (21.87).
It may suggest that Bio-Techneaccelerated paying its suppliers.
Bio-Techne Days Payable Related Terms
Bio-Techne Days Payable Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1TECH vs ARWR, CYTK, KRYS: Days Payable Comparison
For the Biotechnology subindustry, Bio-Techne's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Days Payable distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bio-Techne's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (MIL:1TECH) has a Days Payable of 21.87 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio-Techne and its competitors. This is 28% below median its historical median of 30.20. Over the past decade, Bio-Techne's Days Payable has ranged from 23.55 to 38.32. According to the industry distribution chart, Bio-Techne ranks #607 out of 703 companies in the Biotechnology industry, placing it in the top 86.3%.
Is Bio-Techne's Days Payable too high?
Bio-Techne's current Days Payable of 21.87 is 28% below median its 10-year median of 30.20. Over the past 10 years, this metric has ranged from a low of 23.55 to a high of 38.32. The Biotechnology industry median Days Payable is 113.76. Bio-Techne's value of 21.87 is 80.8% below this industry median. Based on the distribution chart, Bio-Techne ranks #607 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bio-Techne has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Days Payable compare to ARWR and CYTK?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #607 out of 703 companies for Days Payable. This places Bio-Techne in the lower half of its industry. The industry median Days Payable is 113.76. Bio-Techne's value of 21.87 is 80.8% below this benchmark. Historically, Bio-Techne's own Days Payable has ranged from 23.55 to 38.32 over the past decade. While the company's 10-year median is 30.20 vs. the industry median of 113.76, Bio-Techne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Days Payable of 21.87 is 80.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Days Payable is 21.87, which is 28% below median its own 10-year median of 30.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (MIL:1TECH) is currently considered Fairly Valued. The stock's GF Value™ is €63.40, compared to a current price of €62.06 — trading 2.1% below its estimated fair value. The current Days Payable is 21.87, which is 28% below median its 10-year median of 30.20 and 80.8% below the Biotechnology industry median of 113.76. Bio-Techne's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bio-Techne (MIL:1TECH), the current Days Payable is 21.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (MIL:1TECH) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued.
The current stock price of €62.06 is trading 2.1% below its estimated GF Value™ of €63.40.
GuruFocus considers Bio-Techne to be Fairly Valued.
Key valuation signals for MIL:1TECH:
Days Payable: 21.87 (28% below median its 10-year median of 30.20)
GF Value™: €63.40 vs. price of €62.06 (2.1% below fair value)
Industry Position: 80.8% below the Biotechnology median (#607 of 703)
No single metric tells the full story. See the MIL:1TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
61GF Score
Get the complete analysis for MIL:1TECH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1TECH has been successfully added to your 
